457 related articles for article (PubMed ID: 32227058)
41. Self-Assembly Dual-Responsive NO Donor Nanoparticles for Effective Cancer Therapy.
Gu G; Chen C; Zhang S; Yin B; Wang J
ACS Appl Mater Interfaces; 2021 Nov; 13(43):50682-50694. PubMed ID: 34668695
[TBL] [Abstract][Full Text] [Related]
42. A novel carbon-nanodots-based theranostic nano-drug delivery system for mitochondria-targeted imaging and glutathione-activated delivering camptothecin.
Gong X; Wang Z; Zhang L; Dong W; Wang R; Liu Y; Song S; Hu Q; Du F; Shuang S; Dong C
Colloids Surf B Biointerfaces; 2022 Oct; 218():112712. PubMed ID: 35921692
[TBL] [Abstract][Full Text] [Related]
43. Redox-responsive nanoparticles based on Chondroitin Sulfate and Docetaxel prodrug for tumor targeted delivery of Docetaxel.
Li Y; Chen X; Ji J; Li L; Zhai G
Carbohydr Polym; 2021 Mar; 255():117393. PubMed ID: 33436222
[TBL] [Abstract][Full Text] [Related]
44. Preparation of camptothecin-loaded targeting nanoparticles and their antitumor effects on hepatocellular carcinoma cell line H22.
Yang A; Liu Z; Yan B; Zhou M; Xiong X
Drug Deliv; 2016 Jun; 23(5):1699-706. PubMed ID: 25148540
[TBL] [Abstract][Full Text] [Related]
45. A camptothecin-based, albumin-binding prodrug enhances efficacy and safety in vivo.
Cheng Z; Huang Y; Shen Q; Zhao Y; Wang L; Yu J; Lu W
Eur J Med Chem; 2021 Dec; 226():113851. PubMed ID: 34547508
[TBL] [Abstract][Full Text] [Related]
46. Carbonate esters turn camptothecin-unsaturated fatty acid prodrugs into nanomedicines for cancer therapy.
Li Y; Kang T; Wu Y; Chen Y; Zhu J; Gou M
Chem Commun (Camb); 2018 Feb; 54(16):1996-1999. PubMed ID: 29411840
[TBL] [Abstract][Full Text] [Related]
47. The self-assembling camptothecin-tocopherol prodrug: An effective approach for formulating camptothecin.
Lu J; Liu C; Wang P; Ghazwani M; Xu J; Huang Y; Ma X; Zhang P; Li S
Biomaterials; 2015 Sep; 62():176-87. PubMed ID: 26057133
[TBL] [Abstract][Full Text] [Related]
48. Chondroitin sulfate-functionalized polymeric nanoparticles for colon cancer-targeted chemotherapy.
Zu M; Ma L; Zhang X; Xie D; Kang Y; Xiao B
Colloids Surf B Biointerfaces; 2019 May; 177():399-406. PubMed ID: 30785037
[TBL] [Abstract][Full Text] [Related]
49. Dual Stable Nanomedicines Prepared by Cisplatin-Crosslinked Camptothecin Prodrug Micelles for Effective Drug Delivery.
Li Y; Lu H; Liang S; Xu S
ACS Appl Mater Interfaces; 2019 Jun; 11(23):20649-20659. PubMed ID: 31117440
[TBL] [Abstract][Full Text] [Related]
50. Dimeric Prodrug Self-Delivery Nanoparticles with Enhanced Drug Loading and Bioreduction Responsiveness for Targeted Cancer Therapy.
He X; Cai K; Zhang Y; Lu Y; Guo Q; Zhang Y; Liu L; Ruan C; Chen Q; Chen X; Li C; Sun T; Cheng J; Jiang C
ACS Appl Mater Interfaces; 2018 Nov; 10(46):39455-39467. PubMed ID: 30362704
[TBL] [Abstract][Full Text] [Related]
51. Development of pH-Sensitive Cationic PEGylated Solid Lipid Nanoparticles for Selective Cancer-Targeted Therapy.
Chuang CH; Wu PC; Tsai TH; Fang YP; Tsai YH; Cheng TC; Huang CC; Huang MY; Chen FM; Hsieh YC; Lin WW; Tsai MJ; Cheng TL
J Biomed Nanotechnol; 2017 Feb; 13(2):192-03. PubMed ID: 29377649
[TBL] [Abstract][Full Text] [Related]
52. A self-immolative prodrug nanosystem capable of releasing a drug and a NIR reporter for in vivo imaging and therapy.
Wang Z; Wu H; Liu P; Zeng F; Wu S
Biomaterials; 2017 Sep; 139():139-150. PubMed ID: 28614754
[TBL] [Abstract][Full Text] [Related]
53. A polymeric prodrug of cisplatin based on pullulan for the targeted therapy against hepatocellular carcinoma.
Wang Y; Liu Y; Liu Y; Zhou W; Wang H; Wan G; Sun D; Zhang N; Wang Y
Int J Pharm; 2015 Apr; 483(1-2):89-100. PubMed ID: 25681730
[TBL] [Abstract][Full Text] [Related]
54. Hyaluronic Acid-Coated Camptothecin Nanocrystals for Targeted Drug Delivery to Enhance Anticancer Efficacy.
Wang J; Muhammad N; Li T; Wang H; Liu Y; Liu B; Zhan H
Mol Pharm; 2020 Jul; 17(7):2411-2425. PubMed ID: 32437163
[TBL] [Abstract][Full Text] [Related]
55. Effects of surface modification of As
Song X; You J; Shao H; Yan C
Colloids Surf B Biointerfaces; 2018 Sep; 169():289-297. PubMed ID: 29793091
[TBL] [Abstract][Full Text] [Related]
56. In vivo and in situ tracking cancer chemotherapy by highly photostable NIR fluorescent theranostic prodrug.
Wu X; Sun X; Guo Z; Tang J; Shen Y; James TD; Tian H; Zhu W
J Am Chem Soc; 2014 Mar; 136(9):3579-88. PubMed ID: 24524232
[TBL] [Abstract][Full Text] [Related]
57. Self-Assembled Polyprodrug Amphiphile for Subcutaneous Xenograft Tumor Inhibition with Prolonged Acting Time In Vivo.
Chen D; Huang Y; Xu S; Jiang H; Wu J; Jin X; Zhu X
Macromol Biosci; 2017 Nov; 17(11):. PubMed ID: 28737832
[TBL] [Abstract][Full Text] [Related]
58. Redox-sensitive lipophilic prodrugs: delivering unstable chemotherapeutant for improved cancer therapy.
Li F; Huang Z; Chen H; Yan L; Li J; Su Y; Zhang Q; Huang Z; Zheng Y
Drug Deliv; 2019 Dec; 26(1):1068-1079. PubMed ID: 31735094
[TBL] [Abstract][Full Text] [Related]
59. Polyprodrug amphiphiles: hierarchical assemblies for shape-regulated cellular internalization, trafficking, and drug delivery.
Hu X; Hu J; Tian J; Ge Z; Zhang G; Luo K; Liu S
J Am Chem Soc; 2013 Nov; 135(46):17617-29. PubMed ID: 24160840
[TBL] [Abstract][Full Text] [Related]
60. NIR imaging-guided combined photodynamic therapy and chemotherapy by a pH-responsive amphiphilic polypeptide prodrug.
Ruan Z; Liu L; Jiang W; Li S; Wang Y; Yan L
Biomater Sci; 2017 Jan; 5(2):313-321. PubMed ID: 27999839
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
